KDDF

Pipeline (2021-2030)

	Modality	Indication	Targets	Stage	Company	Project No.
1	Completion of Phase 1 Clinical Trial and IND Approval of Phase 2a Clinical Trial for VTB-10, a First-in-Class Treatment for Pulmonary Arterial Hypertension
1	Small molecules	PAH (Pulmonary Arterial Hypertension)	Peroxiredoxin 2 (PRX2)	Phase 1	VASTHERA Co. Ltd.	RS-2026-25501944
2	Discovery of an anticoagulant drug candidate targeting ANO6 that improves bleeding safety
2	Small molecules	Thrombosis	ANO6	Candidate	S2Cbio Inc.	RS-2025-02213140
3	Non-clinical development of novel target PRDX-based treatment for pulmonary arterial hypertension
3	Small molecules	Pulmonary Arterial Hypertension	Peroxiredoxin II (PRDX2)	Preclinical	VASTHERA Co. Ltd.	RS-2024-00338193
4	Development of TNAP inhibitor, A new drug for medical treatment Aortic Stenosis
4	Small molecules	Aortic stenosis	TNAP	Hit	REDNVIA Inc.	RS-2023-00217370
5	Inhaler development with PDGFR small molecule inhibitors for pulmonary arterial hypertension
5	Small molecules	Pulmonary hypertension	PDGFR	Candidate	Voronoi, Inc	RS-2022-00165937
6	Phase II clinical development of DPP-4 inhibitor (Evogliptin), a new drug for medical treatment of Aortic Stenosis
6	Small molecules	Aortic Stenosis	DPP-4	Phase 2	REDNVIA	HN21C1047
7	Determining the efficacy and discovery of optimal lead compounds of a novel class of diuretics, pendrin inhibitors, for treatment of congestive heart failure and chronic kidney disease
7	Small molecules	Congestive heart failure, Chronic renal disease	pendrin	Lead	Yonsei University	HN21C0281

BACK